Cannabis Science Inc (OTCMKTS:CBIS) a company into the development of cannabis-based consulting, reported a major Collaborative Drug Development agreement with IGXBio and its GenePro®, which is a DNA-based immunotherapeutic. The company’s product had recently acquired FDA IND approval to start with human studies. The companies plan to form a joint protocol to show potential synergistic impact of their respective lead drug candidates in HIV.
The expert view
Mr. James Laufenberg, the CEO and President of IGXBio, said that he is excited about this collaborative deal with Cannabis Science, a firm based on their own values of meeting the unmet needs of patients suffering from HIV. The GenePro® technology has been released in more than 150 scientific journals. It is developed to result in an anti-HIV immune response to boost virus control in HIV-infected enrollments. The pre-clinical activities to date have been funded by $21 million received in NIH grants. The deal with Cannabis Science is designed to develop new drugs for clinical development and commercialization.
The significance
Dr. Roscoe M. Moore Jr., the Special Senior Advisor of Cannabis Science, said that inflammation is the immune response of body to HIV that is recorded at even low levels of HIV reproduction. It is a prime factor that leads to the co-morbidities and promotes mortality and morbidity in people with HIV, despite successful antiretroviral treatment such as cancers, heart disease and bone disease. If inflammation can be eliminated or lowered along with HIV viral replication it will largely improve the health of HIV-positive people. By partnering GenePro® and CS-TATI-1, the experts believe it is possible.
The deal
Raymond C. Dabney, the CEO of Cannabis Science Inc (OTCMKTS:CBIS) said that the deal between CBIS and IGX Bio is intended to help offer new insights into the function of inflammation and therapeutic treatment of HIV as a vital measure for optimizing effective treatments for HIV patients.
